DPP3-mediated Destabilization of SLC3A2 Promotes Ferroptosis and Restores Chemosensitivity in Gastric Cancer

In the fight against stomach cancer, doctors often rely on a standard arsenal of chemotherapy drugs designed to damage the DNA inside tumor cells, causing them to self-destruct. However, cancer cells are remarkably adaptable survivors. When faced with this chemical assault, they frequently develop a shield, learning to repair their damaged DNA or neutralize the toxic stress the drugs create, allowing them to keep growing. This ability to resist treatment is the primary reason why many patients do not survive long after a diagnosis. To break through this barrier, scientists are looking for ways to strip these defenses away, forcing the cancer cells to succumb to the very treatments they have learned to ignore. One promising avenue involves a specific type of cell death called ferroptosis. Unlike the more familiar form of cell suicide, ferroptosis is driven by a buildup of rust-like damage within the cell's fats, caused by an excess of reactive oxygen species. If a cancer cell cannot keep this internal rust in check, it bursts and dies. The key to this process often lies in how the cell manages a vital antioxidant called glutathione, which acts like a sponge to soak up the damaging chemicals.

A recent study from researchers at Inner Mongolia People's Hospital and Inner Mongolia University has uncovered a critical piece of this puzzle. They identified a protein called DPP3, which acts as a natural brake on the cancer cell's ability to resist chemotherapy. In healthy cells, DPP3 helps keep things in balance, but in stomach cancer cells that have become resistant to treatment, this protein is often missing or present in very low amounts. The researchers found that when DPP3 is absent, the cancer cells build up a powerful defense system that neutralizes the chemotherapy drugs. Specifically, the lack of DPP3 allows another protein, known as SLC3A2, to become overly stable and active. This SLC3A2 protein functions as a gatekeeper, opening the doors to let in cystine, a building block the cell uses to manufacture glutathione. With too much glutathione, the cancer cell becomes a fortress, scrubbing away the toxic damage before it can kill the cell.

The team demonstrated that when they restored DPP3 levels in these resistant cancer cells, the gatekeeper protein SLC3A2 began to break down. Without SLC3A2, the cells could not import enough cystine to make their protective glutathione. As a result, the internal rust accumulated, triggering ferroptosis and making the cells highly vulnerable to chemotherapy again. In laboratory experiments using human stomach cancer cells, the researchers showed that cells with high levels of DPP3 died much more easily when exposed to platinum-based drugs, while cells lacking DPP3 survived. They confirmed this mechanism by showing that DPP3 physically binds to SLC3A2 and marks it for destruction at both the protein and genetic message levels. This process was not just a theory; the researchers observed it directly in living cells and in animal models where tumors grew from human cancer cells. In mice, tumors that lacked DPP3 grew larger and ignored the chemotherapy, but when the researchers forced those tumors to produce DPP3 again, the drugs worked effectively, shrinking the cancer.

The study also looked at how this mechanism affects the cell's ability to repair its DNA. When chemotherapy damages DNA, the cell usually tries to fix the breaks. The researchers found that cells without DPP3 were surprisingly good at surviving this damage, not because they repaired it faster, but because they prevented the damage from happening in the first place. By keeping their internal environment clean of toxic rust, they avoided the chain reaction that leads to severe DNA breaks. This suggests that DPP3 does not work by helping the cell fix broken DNA, but by keeping the cell so clean that the DNA never gets broken in the first place. This distinction is important because it means the cancer's resistance is rooted in its metabolism—how it eats and manages its internal chemistry—rather than just its repair machinery.

To ensure these findings were not limited to the lab, the team examined actual tissue samples from patients with stomach cancer. They found a clear pattern: patients whose tumors had high levels of DPP3 lived longer than those with low levels. In the tissue samples, the researchers saw an inverse relationship; where DPP3 was low, the protective SLC3A2 protein was high, and the cancer was more aggressive. This clinical evidence supports the idea that DPP3 is a natural tumor suppressor that the cancer tries to silence to survive. The researchers also tested patient-derived organoids, which are tiny, three-dimensional clusters of cancer cells grown from patient tissue. These models behaved exactly like the cells in the mice and the petri dishes, confirming that the DPP3-SLC3A2 axis is a real and powerful factor in human disease.

The implications of this discovery are significant for future treatment strategies. Since DPP3 acts as a switch that turns off the cancer's antioxidant shield, restoring its function could make standard chemotherapy effective again for patients who have developed resistance. The researchers propose that therapies designed to boost DPP3 levels or block the SLC3A2 gatekeeper could be combined with existing platinum-based drugs. This approach would not require inventing entirely new drugs but rather finding a way to reactivate a natural defense mechanism that the cancer has already learned to turn off. While the study does not yet offer a new drug for patients, it provides a clear roadmap for how to overcome one of the most stubborn barriers in treating stomach cancer. By understanding exactly how the cancer builds its shield, scientists can now focus on dismantling it, turning a resistant tumor back into a vulnerable one.